Cokiera EU Withdrawal Signals Abbvie Betting On Glecaprevir/Pibrentasvir
Executive Summary
By pulling its EU marketing authorization application for Hep C therapy Cokiera, AbbVie seems resigned the antiviral can’t adequately compete there against Gilead’s Harvoni and Merck’s Zepatier and that the company will instead await arrival of its more potent, lower priced Glecaprevir/pibrentasvir combo next year.